{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:24:58Z","timestamp":1791379498032,"version":"4.3.3"},"reference-count":27,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Objectives\nLong QT syndrome (LQTS) is described as the development of sudden syncope attacks or death as a result of ventricular tachycardia (VT) episodes that might be observed as elongated QT interval in electrocardiography (ECG). Implantable Cardioverter Defibrillator (ICD) is recommended as first-line treatment for the condition in guidelines. We aimed to present an adolescent recently diagnosed with Bipolar Disorder (BD) who had LQTS that was treated with ICD, discussing her follow up and treatment along with relevant literature.\nMethods\nPsychiatric assessment of the case that applied to our child psychiatry unit due to manic symptoms were carried out by using Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria. Symptom severity was monitored via Young Mania Rating Scale scores (YMRSS).\nResults\nThe case met criteria for Bipolar Disorder Type I (BD-I). She had improvement in her mood symptoms with treatment regimen as risperidone 3 mg\/day, valproate 1000 mg\/day and lorazepam 1 mg\/dayi after her 2\u2013week follow up as well as no reported ICD activity, reflecting fine cardiac functions and rhythm.\nConclusions\nLQTS is a serious health issue for children and adolescents diagnosed with BD. This condition should be kept in mind especially in cases where familial risk factors are present and precautions need to be maintained upon required assessments. These cases need to be closely monitored due to risk factors related to both BD and LQTS, in a multidisciplinary fashion, involving both psychiatry and cardiology divisions.<\/jats:p>","DOI":"10.64719\/pb.4354","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"33-39","source":"Crossref","is-referenced-by-count":0,"title":["Treating an Adolescent with Long QT Syndrome for Bipolar Disorder: A Case Presentation"],"prefix":"10.64719","volume":"47","author":[{"given":"\u00d6zlem","family":"\u00d6nen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u015fe","family":"Kutlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan \u00d6zek","family":"Erkuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Vincent GM. Long QT syndrome. Cardiol Clin. 2000;18(2):309\u2013325.","DOI":"10.1016\/S0733-8651(05)70143-0"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Viskin S. Long QT syndromes and torsade de pointes. Lancet. 1999;354(9190):1625\u20131633.","DOI":"10.1016\/S0140-6736(99)02107-8"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL et al. Spectrum of mutations in long-QT syndrome genes KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102(10):1178\u20131185.","DOI":"10.1161\/01.CIR.102.10.1178"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, Cobbe SM. Congenital and acquired long QT syndrome. Eur Heart J. 2000;21(15):1232\u20131237.","DOI":"10.1053\/euhj.2000.2222"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"EL-SHERIF NA, Turitto G. The long QT syndrome and torsade de pointes. Pacing Clin Electrophysiol. 1999;22(1):91\u2013110.","DOI":"10.1111\/j.1540-8159.1999.tb00305.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM. Proceedings. 3. Vol. 23. Baylor University Medical Center; 2010. Jul 1, Causes and management of drug-induced long QT syndrome. InBaylor University Medical Center; p. 250.","DOI":"10.1080\/08998280.2010.11928628"},{"key":"ref7","unstructured":"Committee for Proprietary Medicinal Products. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the Evaluation of Medicinal Products. 1997;17"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. Dtsch Arztebl Int. 2011;108(41):687\u2013693.","DOI":"10.3238\/arztebl.2011.0687"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Vieweg WV. New generation antipsychotic drugs and QTc interval prolongation. Prim Care Companion J Clin Psychiatry. 2003;5(5):205.","DOI":"10.4088\/PCC.v05n0504"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Nielsen J, Graff C, Kanters JK, Toft E, Taylor D, Meyer JM. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs. 2011;25(6):473\u2013490.","DOI":"10.2165\/11587800-000000000-00000"},{"key":"ref11","unstructured":"Paulussen AD, Aerssens J. Risk factors for drug-induced long-QT syndrome. Netherlands Heart Journal. 2005;13(2):47."},{"key":"ref12","unstructured":"Ewa MJ, Grzegorz H. Non genetic risk factors of long-QT syndrome. Open J Genetics. 2012;2012"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Singh P, Maldonado-Duran JM. Drug-induced QT prolongation as a result of an escitalopram overdose in a patient with previously undiagnosed congenital long QT syndrome. Case reports in medicine. 2014;2014","DOI":"10.1155\/2014\/917846"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J et al. Effectiveness and limitations of \u03b2-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101(6):616\u2013623.","DOI":"10.1161\/01.CIR.101.6.616"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome current knowledge, gaps, and future directions. Circulation. 1996;94(8)","DOI":"10.1161\/01.CIR.94.8.1996"},{"key":"ref16","unstructured":"Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB et al. ACC\/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol. 1998;31(5):1175\u20131209."},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Silka MJ, Kron J, Dunnigan A, Dick M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation. 1993;87(3):800\u2013807.","DOI":"10.1161\/01.CIR.87.3.800"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Heersche JH, Blom NA, Van De Heuvel F, Blank C, Reimer AG, CLUR SA et al. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands. Pacing Clin Electrophysiol. 2010;33(2):179\u2013185.","DOI":"10.1111\/j.1540-8159.2009.02603.x"},{"key":"ref19","unstructured":"Karag\u00f6z T, \u00c7eliker A, \u00d6zer S. \u00c7ocuklarda ve eri\u015fkin konjenital kalp hastalikli hastalarda implante edilebilir kardiyoverter defibrilat\u00f6r implantasyonu. T\u00fcrk Aritmi Pacemaker ve Elektrofizyolojisi Dergisi. 2006;4(1)"},{"key":"ref20","unstructured":"Woosley RL, Romero KA. CredibleMeds QTdrugs List (\u0130nternet) Arizona: Azcert, Inc; 2013. Available from: https:\/\/crediblemeds.org\/#sthash.W7zmT40s.dpuf."},{"key":"ref21","unstructured":"FDA Briefing Document for Zeldox Capsules (Ziprasidone) New York: Pfizer Inc; 2000. p. p:116."},{"key":"ref22","unstructured":"Washington NB, Brahm NC, Kissack J. Which psychotropics carry the greatest risk of QTc prolongation? Current Psychiatry. 2012;11(10):36."},{"key":"ref23","unstructured":"Dallaire S. Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval. CMAJ. 2001;(1):164. 91."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Shapiro BA, Warren J, Egol AB, Greenbaum DM, Jacobi J, Nasraway SA et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Crit Care Med. 1995;23(9):1596\u20131600.","DOI":"10.1097\/00003246-199509000-00021"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Modai I, Hirschmann S, Rava A, Kurs R, Barak P, Lichtenberg P et al. Sudden death in patients receiving clozapine treatment: a preliminary investigation. J Clin Psychopharmacol. 2000;20(3):325\u2013327.","DOI":"10.1097\/00004714-200006000-00006"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62(11):1649\u20131671.","DOI":"10.2165\/00003495-200262110-00006"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol. 2008;51(17):1685\u20131691.","DOI":"10.1016\/j.jacc.2008.01.033"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:26:27Z","timestamp":1791314787000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/treating-an-adolescent-with-long-qt-syndrome-for-bipolar-disorder-a-case-presentation\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4354","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}